Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market, with €15.5 million raised

Paris, France, October 27, 2021– ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company specialized in the development of drugs for treating cardiovascular emergencies, today announces the success of its Initial Public Offering on the Euronext Growth marketin Paris.
Paris, France, October 27, 2021– ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company specialized in the development of drugs for treating cardiovascular emergencies, today announces the success of its Initial Public Offering on the Euronext Growth market in Paris. Gilles AVENARD, Chief Executive Officer of Acticor Biotech, states: “On behalf of the entire team, I would like to thank our historical shareholders who took part in this transaction and to the new shareholders who enabled it to be a success. Thanks to these funds, it is with determination that we will be able to accelerate our clinical developments in the treatment of cardiovascular emergencies, which remain a crucial public health challenge. We are proud to be one of the few listed companies in the world which specializes in developing a new drug for ischemic strokes. This focus makes ACTICOR a unique investment vehicle for our shareholders, and we will do everything we can to successfully meet the next stages of our developments”.

Related posts

acticor
admin

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.

Read More »
DigitalHealth
admin

Incepto, the French Digital Health Specialist, is Raising €27 million to Support Its European Development

Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today.

Read More »